Drilldown: Medicines
Appearance
Medicines > fda max
:
Indication-specific
or
Rheumatologic ~25 mg/week; oncology indication-specific
& halflife:
Not well characterized 
:
Indication-specific
or
Rheumatologic ~25 mg/week; oncology indication-specific
& halflife:
Not well characterized 
Use the filters below to narrow your results.
There are no results for this report.

